论文部分内容阅读
42kD恶性疟原虫裂殖子表面蛋白质 1C末端片段 (MSP1 42 )是当今重要的疟疾疫苗候选抗原。为获得大量构象正确的MSP1 42重组蛋白进行疫苗有效性试验 ,在毕氏酵母系统中分泌表达了MSP1 42重组蛋白。通过与一组特异性识别构象表位的单抗反应 ,该重组蛋白在重要构象表位上与天然蛋白质一致。由该蛋白质诱生的抗体能有效地抑制恶性疟原虫的体外生长 ,这些结果为进一步开展MSP1 42重组蛋白疫苗有效性试验提供了基础
The 42kD Plasmodium falciparum merozoite surface protein 1C fragment (MSP1 42) is a candidate malaria vaccine antigen of importance today. In order to obtain a large number of conformationally correct MSP1 42 recombinant proteins for vaccine effectiveness test, the recombinant Pichia pastoris MSP1 42 protein was secreted. The recombinant protein is identical to the native protein in the important conformational epitope by reaction with a set of monoclonal antibodies that specifically recognize the conformational epitope. Antibodies induced by this protein can effectively inhibit the growth of Plasmodium falciparum in vitro. These results provide the basis for further testing the effectiveness of MSP1 42 recombinant protein vaccine